Do Asthma Inhalers Raise Blood Sugar?

Standard-dose asthma inhalers cause little or no meaningful rise in blood sugar for most people. The inhaled corticosteroids used for daily maintenance and the short-acting bronchodilators used for rescue both deliver medication primarily to the lungs, with only a small fraction reaching the bloodstream. That said, the picture gets more complicated at higher doses, with long-term use, and for people who already have diabetes or prediabetes. The relationship between inhalers and blood sugar is not a simple yes-or-no question, and the type of inhaler matters.

Two Different Inhalers, Two Different Concerns

When people ask whether asthma inhalers raise blood sugar, they’re usually thinking about one of two types of medication. The first is the inhaled corticosteroid (ICS), the “controller” or “preventer” inhaler you use every day to keep inflammation down. Common examples include fluticasone, budesonide, and beclomethasone. The second is the short-acting beta-agonist (SABA) like albuterol (salbutamol), the “rescue” inhaler you grab when you’re wheezing. Each one has a different mechanism and a different risk profile when it comes to blood sugar.

Oral corticosteroids, the kind you swallow as pills or get through an IV during a bad asthma flare, are well known to spike blood sugar. That’s not controversial. The question with inhaled corticosteroids is whether enough of the drug leaks into your system to produce the same effect. And with beta-agonists, the concern is whether stimulating certain receptors can nudge glucose levels upward on their own.

Inhaled Corticosteroids at Standard Doses

The weight of the evidence is reassuring for people using standard doses. A study of asthmatic patients measured fasting blood sugar, HbA1c, insulin levels, and insulin resistance (using the HOMA-IR index) before and after two months of inhaled corticosteroid therapy. None of these values changed significantly.¹ A separate study tracking asthmatic children on continuous inhaled corticosteroids for six months found that HbA1c levels stayed stable, and the duration of therapy and the doses used did not significantly affect those levels.² A large database study of asthma and COPD patients also found no increased risk of new-onset diabetes or hyperglycemia from inhaled corticosteroid treatment.³

In children specifically, research comparing low-dose and high-dose inhaled steroids (up to 400 micrograms daily) found no statistically significant difference in HbA1c, fasting blood sugar, or lipid profiles between the two groups.⁴ The takeaway from these smaller studies is consistent: at the doses most people use day-to-day, inhaled corticosteroids don’t meaningfully disturb glucose metabolism.

The High-Dose and Long-Term Picture Is Murkier

Where the evidence starts to shift is at the high end of the dosing range. A large Canadian cohort study found that current use of inhaled corticosteroids was associated with a roughly 34% increase in the rate of diabetes, after adjusting for other factors. The relationship followed a dose-response curve: the highest doses, equivalent to fluticasone 1000 micrograms per day or more, were linked to a 64% increase in diabetes rates.⁵ A review of the literature confirmed that multiple large observational studies have found an association between high-dose inhaled corticosteroids and both new diabetes cases and worsened control of existing diabetes, though the contribution of other risk factors remains hard to untangle.⁶

This creates an important distinction. A person on a low-to-moderate daily dose of an inhaled corticosteroid is probably not experiencing any clinically relevant blood sugar effect. A person on a high dose for months or years, especially someone who is already at risk for diabetes, should be aware of the possibility. The disconnect between the smaller clinical studies (which tend to show no effect) and the large observational studies (which detect a signal at high doses) likely comes down to dosing, duration, and the sheer numbers needed to spot a modest effect. A trial following 48 patients for two months won’t detect a risk that only shows up after years of use in a subset of vulnerable people.

Why Some Corticosteroid Gets Into Your Blood

When you use a metered-dose inhaler, not all of the drug reaches your lungs. A portion lands in the back of your throat and gets swallowed, entering the bloodstream through the gut. Another portion is absorbed from the lungs themselves. The total amount that ends up circulating through your body is called the systemic bioavailability, and it varies depending on the drug, the device, and your technique.

One study comparing delivery devices found that using a spacer with a metered-dose inhaler roughly halved the systemic effect of budesonide, as measured by morning cortisol suppression. Without a spacer, suppression reached about 73%; with a spacer, it dropped to about 42%.⁷ Mouth rinsing after using a dry-powder inhaler also reduces systemic absorption, because it clears the drug deposited in the throat before it can be swallowed.⁸ These practical steps are straightforward, and they genuinely reduce how much corticosteroid enters your bloodstream.

Rescue Inhalers and Blood Sugar

Albuterol and similar beta-agonist rescue inhalers work by relaxing the smooth muscle around your airways. Beta-agonists are known to promote the breakdown of glycogen into glucose in the liver, and there has been a long-standing question about whether repeated doses could push blood sugar upward. The clinical data, however, are reassuring. A controlled study gave nebulized albuterol to patients with diabetes (both with and without cystic fibrosis) and compared the results to a placebo. The average maximum blood sugar increase from baseline was modest, and the difference between albuterol and placebo was not statistically significant. The researchers concluded that a standard nebulized dose of albuterol causes no clinically significant rise in blood glucose.⁹

Older research into the mechanisms of blood sugar changes during acute asthma treatment found no evidence that beta-agonists directly stimulated the pancreatic islet cells in a way that disrupted insulin regulation.¹⁰ When blood sugar does rise during an asthma attack, the more likely culprits are the stress hormones your body releases in response to low oxygen and the systemic steroids you may receive in the emergency room, not the rescue inhaler itself.

Why Asthma Attacks Confuse the Picture

One reason this question keeps coming up is that people with asthma sometimes notice their blood sugar climbing during a flare-up and blame the inhaler. But during an exacerbation, many things are happening at once. You’re stressed, your body is flooding itself with cortisol and adrenaline, and if you end up in the hospital, you may receive oral or intravenous corticosteroids at doses that dwarf what you’d get from an inhaler. A study of hospitalized patients with asthma and COPD exacerbations found that hyperglycemia was very common in that setting, but that it was probably triggered by the medications (particularly systemic steroids) combined with the patient’s underlying metabolic predisposition.¹¹

So if your blood sugar spiked during an asthma attack, the most likely explanation is the oral steroid burst your doctor prescribed (like prednisone), your body’s own stress response, or both. The controller inhaler you use at home on normal days deserves far less suspicion.

What This Means If You Already Have Diabetes

For people who already live with type 2 diabetes or prediabetes, even a small metabolic nudge from an inhaled corticosteroid can be more consequential. A crossover trial in type 2 diabetics compared six weeks of inhaled fluticasone against six weeks of montelukast (a non-steroid asthma controller pill). The average HbA1c change during the fluticasone period was small (about a quarter of a percentage point higher than during the montelukast period), but it was statistically significant.¹² A quarter of a percentage point in HbA1c is not a dramatic shift, but over time it could matter for someone already struggling with glucose control.

Review papers have summarized this pattern: the systemic bioavailability of inhaled corticosteroids is generally considered minimal, and side effects are often called negligible, yet large retrospective cohorts have detected worsening glycemic control in people with pre-existing diabetes who use them.¹³ If you have diabetes and your doctor prescribes an inhaled corticosteroid, this is not a reason to refuse it. Uncontrolled asthma carries its own serious risks. But it is a reason to mention it to whichever provider manages your diabetes, so they can monitor your glucose a bit more closely and adjust your diabetes medications if needed.

Reducing Your Exposure in Practice

If you’re concerned about systemic effects, there are simple steps that can minimize how much corticosteroid enters your bloodstream. These are worth doing regardless of blood sugar concerns, because they also reduce oral thrush and hoarseness.

Use a spacer: Attaching a valved holding chamber (spacer) to your metered-dose inhaler dramatically cuts the amount of drug deposited in your throat. Less throat deposition means less swallowed drug reaching your gut and blood.
Rinse and spit: After every puff of an inhaled corticosteroid, rinse your mouth thoroughly and spit the water out. This clears the drug that landed in your mouth and throat before it can be absorbed.¹⁴
Use the lowest effective dose: Work with your doctor to find the minimum dose that keeps your asthma controlled. Step-down therapy, where you gradually reduce the dose once you’ve been stable for a while, is standard practice and reduces systemic exposure.

These measures are especially important for people on high-dose regimens, children, and anyone with diabetes risk factors.

Not All Inhaled Corticosteroids Are Equal

Different corticosteroid molecules have different pharmacological properties, and some are designed specifically to minimize systemic absorption. Ciclesonide, for instance, is a “pro-drug” that is inactive until it reaches the lungs, where an enzyme converts it to its active form. It has low oral bioavailability, is heavily protein-bound in the blood (meaning less free drug available to affect other tissues), and is cleared from the body quickly. These properties make it an effective treatment option with a low side-effect profile.¹⁵

Budesonide and fluticasone have different rates of systemic absorption depending on which device delivers them. As noted earlier, budesonide via a dry-powder turbohaler showed a substantially different systemic effect than budesonide via a metered-dose inhaler with a spacer.⁷ For people who are metabolically vulnerable, asking your doctor whether a molecule like ciclesonide or a specific device combination might be a better fit is a reasonable conversation to have.

Drug Interactions That Can Amplify the Problem

One underappreciated factor is drug interactions. Inhaled corticosteroids, particularly fluticasone and budesonide, are broken down in the liver by an enzyme system called CYP3A4. If you also take a medication that strongly inhibits that enzyme, the inhaled corticosteroid can accumulate in your body at much higher levels than intended. The most common culprits are certain HIV medications (protease inhibitors like ritonavir) and antifungal drugs (like itraconazole and ketoconazole).¹⁶

When this happens, what should be a locally-acting inhaled drug effectively becomes a systemic corticosteroid. There have been case reports of patients developing full-blown Cushing syndrome, adrenal suppression, and severe hyperglycemia from what appeared to be ordinary inhaled corticosteroid therapy, simply because a co-prescribed medication was blocking the drug’s clearance. If you take a protease inhibitor or an azole antifungal, make sure your prescriber knows you’re also using an inhaled corticosteroid. A switch to beclomethasone, which uses a different metabolic pathway, is one common workaround.

Children and Inhaled Corticosteroids

Parents often worry about long-term medication effects on their children, and blood sugar is a natural concern. The pediatric evidence is largely reassuring. One study of children on budesonide found that a high dosage did temporarily increase the ratio of insulin to blood glucose during a glucose tolerance test, suggesting the pancreas was working harder. But when the dosage was lowered, that ratio actually dropped below baseline.¹⁷ Glucose tolerance itself was not significantly affected at either dose, and neither were cholesterol or triglyceride levels.

A second study in children comparing low-dose and high-dose inhaled steroids (up to 400 micrograms per day) found no significant differences in HbA1c, fasting blood sugar, or lipid profiles between the two groups, concluding that increasing the daily dose within that range does not alter carbohydrate metabolism.⁴ And a six-month pilot study in asthmatic children found stable HbA1c levels throughout, with only a small fraction showing prediabetic readings, and no relationship between those readings and the dose or duration of inhaled corticosteroid therapy.² For the overwhelming majority of children, inhaled steroids at recommended doses don’t pose a meaningful blood sugar risk.

When to Actually Worry

Pulling together the evidence across these different angles, a few practical guidelines emerge. If you use a low-to-moderate dose of an inhaled corticosteroid and you don’t have diabetes, the chance of a clinically important blood sugar effect is very low, and the risk of poorly controlled asthma far outweighs the theoretical metabolic concern. If you have existing type 2 diabetes or strong risk factors for it, and you’re on a high dose, your blood sugar monitoring schedule is worth discussing with your provider. If you take a CYP3A4 inhibitor alongside your inhaled corticosteroid, you may be getting far more systemic steroid exposure than anyone intended. And if your blood sugar has risen during or after an asthma exacerbation, look first at the oral steroids and the body’s stress response before blaming the inhaler.

Rescue inhalers are essentially a non-issue for blood sugar in everyday use. They work locally, clear quickly, and controlled trials in diabetic patients have not found clinically significant glucose increases from standard doses. The conversation about blood sugar and asthma inhalers is almost entirely a conversation about inhaled corticosteroids, and within that category, it’s largely a conversation about dose, duration, and individual vulnerability.

1
Monaldi Archives for Chest Disease. The effects of inhaled corticosteroid on insulin sensitivity in asthmatic patients
2
Egyptian Pediatric Association Gazette. Effect of continuous inhaled corticosteroids on glycated hemoglobin in asthmatic children: a pilot study
3
PubMed. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids
4
Indian Journal of Allergy, Asthma and Immunology. Glycosylated hemoglobin levels and lipid profile in children with asthma using low dose and high dose inhaled corticosteroids
5
The American Journal of Medicine. Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression
6
PubMed Central. Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review
7
PubMed. Systemic bioavailability and potency of high-dose inhaled corticosteroids: a comparison of four inhaler devices and three drugs in healthy adult volunteers
8
Thorax. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler
9
PubMed. Effect of nebulized albuterol on blood glucose in patients with diabetes mellitus with and without cystic fibrosis
10
QJM: An International Journal of Medicine. Mechanisms of Abnormal Glucose Metabolism During the Treatment of Acute Severe Asthma
11
PubMed. Hyperglycaemia during exacerbations of asthma and chronic obstructive pulmonary disease
12
PubMed Central. The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes
13
PubMed Central. Effect of inhaled corticosteroids on glycemic status
14
Respiratory Medicine. Systemic side effects of inhaled corticosteroids in patients with asthma
15
PubMed. Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids
16
PubMed Central. Drug Interactions With Oral Inhaled Medications
17
Journal of Allergy and Clinical Immunology. Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide